drugset / Trial / NCT00692770

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770

Phase 3 Completed 1114 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).

Timeline

Start
2008-08-15
Primary completion
2013-11-29
Completion
2014-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral